David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045
2017 ASCO Annual MeetingDavid I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizumab vs paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer. (Abstract 4501)
Related Videos
Lisa A. Carey, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial
Lisa A. Carey, MD, of the University of North Carolina, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olap...
David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on mo...
Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials
Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts o...
Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatme...
John Marshall, MD, and Qian Shi, PhD, on Colon Cancer: Results of the IDEA Trial
John Marshall, MD, of Georgetown University, and Qian Shi, PhD, of the Mayo Clinic, discuss study findings on shortening the duration of adjuvant oxaliplatin-based...
